Pilot fMRI Studies of Aging-Related Effects of THC
Yale University
10 participants
Jul 1, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to begin investigating acute impairment of various forms of memory and learning by Tetrahydrocannabinol (THC) in cannabis (CNB) compared to placebo, in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design in young to middle-aged adults.
Eligibility
Inclusion Criteria3
- CNB use within past 2 years and felt "high" when used.
- Able to read, speak, and understand English.
- Able and willing to provide written informed consent, and willing to commit to the study protocol.
Exclusion Criteria15
- Current marijuana tolerance, desire to cut down, or cravings to use during periods of abstinence.
- Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment
- History of adverse effects with CNB
- CNB users who are abstaining
- IQ \<80 on the Wechsler Abbreviated Scale of Intelligence
- Inability to comprehend written instructions using the WRAT 4 reading achievement test
- Pregnant, breastfeeding, and ineffective birth control methods
- Unable or unsafe to have an MRI
- Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy
- History of head trauma with loss of consciousness \> 30 minutes or concussion lasting 30 days
- Focal brain lesion seen on structural MRI
- Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome)
- Anyone deemed unsafe to study personnel for any reason
- Hearing loss such that subject cannot hear sounds at the levels (dB) or pitches (Hz) to be used in the study
- Significant pain and/or reduced mobility in the arms
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)
Participants will be administered identical plant material from which all THC has been removed by solvent extraction.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06647524